Abogen, a pioneering biotech firm, presented promising preliminary results for their new mRNA therapy ABO2203 at the AACR 2026 conference in San Diego, showcasing safety and efficacy in treating relapsed B-cell lymphoma.

Innorna has achieved a significant milestone with FDA approval for their mRNA-based therapy IN026, targeting refractory gout in patients. This innovation aims to transform treatment options for chronic metabolic diseases.

Innorna announced FDA's approval of IND for IN026, paving the way for innovative mRNA therapies targeting chronic metabolic diseases, including refractory gout.

Innorna has announced FDA clearance for IN026, an mRNA therapy targeting refractory gout, marking a significant advancement in chronic disease management.

Innorna has announced FDA clearance for IN026, an mRNA-based treatment targeting refractory gout, set to revolutionize chronic disease therapy.

Innorna has received FDA IND clearance for IN026, an innovative mRNA-based therapy aimed at treating refractory gout, potentially revolutionizing treatment options for patients.

Immorta Bio has unveiled a groundbreaking patent application for SenoVax™, an innovative immunotherapy aimed at combating aging and cancer. This first-of-its-kind approach targets senescent cells.

iLeukon Therapeutics presents encouraging Phase I trial data for ILKN421H, showcasing its potential in treating advanced solid tumors at the SITC 2025 conference.

iLeukon Therapeutics has received FDA approval for a Phase II trial of ILKN421H, an mRNA immunotherapy for advanced non-small cell lung cancer, showcasing impressive efficacy.

Explore the future of mRNA analytics in an insightful webinar hosted by Xtalks. Learn about modular platforms and their role in evolving therapies.

Grann Pharmaceuticals marks a pivotal milestone in developing therapies for Rett Syndrome, offering hope to affected families.